App-Quantinova.ai

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

Christine A. Parkinson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade serous ovarian cancer

TP53

Exploring the utility of exosomal HER receptor dimerization as a resistance mechanism in NSCLC.

Myria Galazi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cisplatin

Combining FoxP3 and Helios with GARP/LAP markers to identify expanded Treg subsets in cancer patients.

Eyad Elkord - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Whole body diffusion-weighted MRI in metastatic breast cancer patients: A single centres experience.

Priya V. Joshi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study.

Carlo Palmieri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Irosustat

Structure-activity relationships (SAR) and mechanistic analysis of clinical-stage anti-cancer small molecule ONC201 analogues.

Jessica Wagner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TIC 10

Digital image analysis of automated mRNA in situ hybridization and immunohistochemistry to quantify HER3 expression in cancer tissues.

Malik Khenkhar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Targeting the mitochondria for the treatment of MLH1-deficient disease.

Sukaina Rashid - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

In vivo monitoring of the TR4 anti-Notch fusion protein: an imaging approach.

Agamemnon A. Epenetos - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Optomagnetic imaging spectroscopy (OMIS) as a novel method in the characterization of cervical smears.

Khalil Razvi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Differing pattern of biological characteristics of early operable primary breast cancer according to age.

Binafsha Manzoor Syed - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Potential of a novel technique for constructing tissue microarrays from core needle biopsy as seen in older women with primary breast cancer.

Mohammad A Albanghali - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Targeted Therapy for Advanced Solid Tumors Based on Molecular Profiles: Early Results from MyPathway, an Open-Label, Phase IIa Multiple Basket Study

John D. Hainsworth - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab

Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.

Martin J. Van Den Bent - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

Temozolomide

ESPAC-4: A multicenter, international, open-label randomized controlled phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP) Versus Monotherapy Gemcitabine in Patients with Resected Pancreatic Ductal Adenocarcinoma

John P. Neoptolemos - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

Capecitabine

Atezolizumab as 1L Therapy in Cisplatin-Ineligible Locally Advanced/Metastatic Urothelial Carcinoma: IMvigor210 Cohort 1

Arjun Vasant Balar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Atezolizumab

OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).

Helen Mackay - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

Carboplatin

Global differences in cancer drug prices: A comparative analysis.

Daniel A. Goldstein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The EASI-SWITCH Trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis.

Caroline Forde - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neutropenic Sepsis

Piperacillin/tazobactam

Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer.

Julie R. Nangia - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

taxane

Filters

45280 Abstracts